405103-68-6

Usage

Uses

Used in Pharmaceutical Applications:
2-(Chloromethyl)-6-methoxypyridine is used as a pharmaceutical intermediate for the synthesis of various drugs. Its unique functional groups allow for the development of new compounds with potential therapeutic properties.
Used in Chemical Reactions:
In the chemical industry, 2-(Chloromethyl)-6-methoxypyridine is used as a building block or intermediate in the synthesis of a wide range of organic compounds. Its reactivity makes it a valuable component in the creation of new molecules with specific functions and applications.
Physical properties and safety information for 2-(Chloromethyl)-6-methoxypyridine, such as molecular weight and melting point, can be found on Material Safety Data Sheets (MSDS), which are standard documentation for all industrial chemicals.

InChI:InChI=1/C7H8ClNO/c1-10-7-4-2-3-6(5-8)9-7/h2-4H,5H2,1H3

Upstream product

• 63071-12-5 (6-methoxy-pyridin-2-yl)-methanol 
• 40473-07-2 6-bromo-2-methoxypyridine 
• 26256-72-4 6-methoxy-pyridine-2-carboxylic acid methyl ester 
• 83621-01-6 2-cyano-6-methoxypyridine 
• 19621-92-2 6-Hydroxypicolinic acid 

Downstream Products

• 936340-73-7 3-(3-(4-(6-methoxy-pyridin-2-ylmethoxy)-benzyl)-isoxazol-5-yl)-pyridin-2-ylamine 

Relevant academic research and scientific papers

FUSED PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON FMS KINASES

Disclosed are a fused pyrimidine derivative of formula (I), and a pharmaceutically acceptable salt, stereoisomer, hydrate and solvate thereof, which have an excellent inhibitory activity on FMS kinases, and a pharmaceutical composition comprising the same is effective in preventing or treating diseases caused by abnormal activation of FMS kinases such as immunologic diseases, metabolic diseases, inflammatory diseases, cancers and tumors.

IMIDAZOTRIAZINONE COMPOUNDS

The present invention provides imidazotriazinone compounds which are inhibitors of phosphodiesterase 9 and pharmaceutically acceptable salt thereof. The present invention further provides processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of PDE9 associated diseases or disorders in mammals, including humans.

IMIDAZOTRIAZINONE COMPOUNDS

The present invention provides imidazotriazinone compounds which are inhibitors of phosphodiesterase 9. The present invention further provides processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of PDE9 associated diseases or disorders in mammals, including CNS or neurodegeneration disorder.

3 -M0N0- AND 3 , 5-DISUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS

The invention relates to 3,5-piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (= disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,5- piperidine compound, and/or a method of treatment comprising administering a 3,5- piperidine compound, a method for the manufacture of a 3,5-piperidine compound, and novel intermediates and partial steps for their synthesis. Especially, the 3,5-piperidine compounds have the formula I, wherein the symbols have the meanings described in the specification.